bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figure S1 from Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression
Authors: van der Sluis Tetje C. , Sluijter Marjolein , van Duikeren Suzanne , West Brian L. , Melief Cornelis J.M. , Arens Ramon , van der Burg Sjoerd H. , van Hall Thorbald
Published: April 2023

Mice were inoculated on day 0 with 1 x 105 tumor cells. On day 9, when a palpable tumor was present, mice were treated with HPV16 E743-77 peptide in IFA. A) The frequency of myeloid cells in the live gate is indicated. B) Shown is a graph of tumor sizes in mm2 ten days after vaccination. Shown is the mean + SEM of eight mice per group.
Supplementary Figures from Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Authors: Cooper Zachary A. , Juneja Vikram R. , Sage Peter T. , Frederick Dennie T. , Piris Adriano , Mitra Devarati , Lo Jennifer A. , Hodi F. Stephen , Freeman Gordon J. , Bosenberg Marcus W. , McMahon Martin , Flaherty Keith T. , Fisher David E. , Sharpe Arlene H. , Wargo Jennifer A.
Published: April 2023

Supplementary Figure 1. BP cells behave like classic BRAFV600E melanomas after BRAF inhibition. Supplementary Figure 2. Subcutaneously implanted BP cells develop into tumors. Supplementary Figure 3. BRAF inhibition is associated with an increase in density of tumor-infiltrating T cells. Supplementary Figure 4. Kinetics of functional CD8 T cell markers. Supplementary Figure 5. BRAF inhibition is associated with an increase in overall PD-L1 and PD-L2 expression in the tumor. Supplementary Figure 6. Cell type specific changes in PD-L1 expression after BRAF inhibitors. Supplementary Figure 7. PD-1 or PD-L1 blockade synergy with BRAF inhibitors is associated with increased density of tumor-infiltrating T cells.
Supplemental Table S2 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Authors: Tchou Julia , Zhao Yangbing , Levine Bruce L. , Zhang Paul J , Davis Megan M. , Melenhorst Jan Joseph , Kulikovskaya Irina , Brennan Andrea L , Liu Xiaojun , Lacey Simon F. , Posey Avery D. , Williams Austin D. , So Alycia , Conejo-Garcia Jose R. , Plesa Gabriela , Young Regina M. , McGettigan Shannon , Campbell Jean , Pierce Robert H. , Matro Jennifer M. , DeMichele Angela M. , Clark Amy S. , Cooper Laurence J. , Schuchter Lynn M. , Vonderheide Robert H. , June Carl H.
Published: April 2023

S2. Comprehensive list of all adverse events based on CTCAE v4.0 grading from Day -2 (IT injection) to Day +25.
Supplemental Information and Legends from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Authors: Tchou Julia , Zhao Yangbing , Levine Bruce L. , Zhang Paul J , Davis Megan M. , Melenhorst Jan Joseph , Kulikovskaya Irina , Brennan Andrea L , Liu Xiaojun , Lacey Simon F. , Posey Avery D. , Williams Austin D. , So Alycia , Conejo-Garcia Jose R. , Plesa Gabriela , Young Regina M. , McGettigan Shannon , Campbell Jean , Pierce Robert H. , Matro Jennifer M. , DeMichele Angela M. , Clark Amy S. , Cooper Laurence J. , Schuchter Lynn M. , Vonderheide Robert H. , June Carl H.
Published: April 2023

Supplemental Information and Legends
Figures S1 - S5 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Authors: Tchou Julia , Zhao Yangbing , Levine Bruce L. , Zhang Paul J , Davis Megan M. , Melenhorst Jan Joseph , Kulikovskaya Irina , Brennan Andrea L , Liu Xiaojun , Lacey Simon F. , Posey Avery D. , Williams Austin D. , So Alycia , Conejo-Garcia Jose R. , Plesa Gabriela , Young Regina M. , McGettigan Shannon , Campbell Jean , Pierce Robert H. , Matro Jennifer M. , DeMichele Angela M. , Clark Amy S. , Cooper Laurence J. , Schuchter Lynn M. , Vonderheide Robert H. , June Carl H.
Published: April 2023

S1. Clinical trial schema. S2. Representative immunohistochemistry (IHC). S3. Histology and IHC of tumor tissue pre and post intratumoral injection of RNA CAR T c- Met from one patient. S4. Histology and IHC of tumor tissue pre and post intratumoral injection with lidocaine (1 mL) and RNA CAR T c-Met (1 mL) from another patient. S5. Characterization of CD68+ tumor infiltrated immune cells using multiplex IHC analyses as described (1) in pre and post IT injection of RNA CAR T c-Met tumor tissue sections from two patients.
Supplementary Table 4 from The Tumor Microenvironment Shapes Lineage, Transcriptional, and Functional Diversity of Infiltrating Myeloid Cells
Authors: Elpek Kutlu G. , Cremasco Viviana , Shen Hua , Harvey Christopher J. , Wucherpfennig Kai W. , Goldstein Daniel R. , Monach Paul A. , Turley Shannon J.
Published: April 2023

XLSX file - 4K, Supplementary Table S4: Expression values for neutrophil cytokine-chemokine genes from the heatmap in Figure 6B.
Supplementary Figure 2 from The Tumor Microenvironment Shapes Lineage, Transcriptional, and Functional Diversity of Infiltrating Myeloid Cells
Authors: Elpek Kutlu G. , Cremasco Viviana , Shen Hua , Harvey Christopher J. , Wucherpfennig Kai W. , Goldstein Daniel R. , Monach Paul A. , Turley Shannon J.
Published: April 2023

PDF file - 42K, Supplementary Figure S2: Additional figures on myeloid cell characterization based on tumor type and anatomical location.
Supplementary tables from Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors
Authors: Nirmal Ajit J. , Regan Tim , Shih Barbara B. , Hume David A. , Sims Andrew H. , Freeman Tom C.
Published: April 2023

Tables 1 to 5
Figure S2 from Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors
Authors: Nirmal Ajit J. , Regan Tim , Shih Barbara B. , Hume David A. , Sims Andrew H. , Freeman Tom C.
Published: April 2023

Supplementary Figure 2
Supplementary Table 1 from Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation
Authors: Van Allen Eliezer M. , Golay Hadrien G. , Liu Yan , Koyama Shohei , Wong Karrie , Taylor-Weiner Amaro , Giannakis Marios , Harden Maegan , Rojas-Rudilla Vanesa , Chevalier Aaron , Thai Tran , Lydon Christine , Mach Stacy , Avila Ada G. , Wong Joshua A. , Rabin Alexandra R. , Helmkamp Joshua , Sholl Lynette , Carter Scott L. , Oxnard Geoffrey , Janne Pasi , Getz Gad , Lindeman Neal , Hammerman Peter S. , Garraway Levi A. , Hodi F. Stephen , Rodig Scott J. , Dranoff Glenn , Wong Kwok-Kin , Barbie David A.
Published: April 2023

Table S1: All somatic mutations and short insertion/deletions. This table provides information on all somatic point mutations and short insertion/deletions observed in the tumor sample from this patient. Additional annotations about protein change, allelic fraction, copy ratio (as segment mean), and other information are provided.
Supplementary Figure 1 from Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells—A Key Role for Heat-Shock Protein 70 and Receptor CD91
Authors: Salimu Josephine , Spary Lisa K. , Al-Taei Saly , Clayton Aled , Mason Malcolm D. , Staffurth John , Tabi Zsuzsanna
Published: April 2023

Microscope images of Hsp70 in irradiated tumour cells.
Supplementary Table 1 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Authors: Ohmatsu Hanako , Humme Daniel , Gulati Nicholas , Gonzalez Juana , Möbs Markus , Suárez-Fariñas Mayte , Cardinale Irma , Mitsui Hiroshi , Guttman-Yassky Emma , Sterry Wolfram , Krueger James G.
Published: April 2023

PDF file - 54K, Primers and probes used for Quantitative RT-PCR assay.
Supplementary Figure Legend from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Authors: Ohmatsu Hanako , Humme Daniel , Gulati Nicholas , Gonzalez Juana , Möbs Markus , Suárez-Fariñas Mayte , Cardinale Irma , Mitsui Hiroshi , Guttman-Yassky Emma , Sterry Wolfram , Krueger James G.
Published: April 2023

PDF file - 37K
Supplementary Tables 1 - 2 from Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial
Authors: Chowdhury F. , Johnson P.W. , Glennie M.J. , Williams A.P.
Published: April 2023

PDF file - 45K, Table S1: Demographics of patients treated in each ChiLob 7/4 dose cohort. Table S2: Description of the adverse reactions attributable to a cytokine release syndrome within cohort 4 at the 16mg dose level.
Supplementary Table S1 from Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status
Authors: Broodman Ingrid , VanDuijn Martijn M. , Stingl Christoph , Dekker Lennard J.M. , Germenis Anastasios E. , de Koning Harry J. , van Klaveren Rob J. , Aerts Joachim G. , Lindemans Jan , Luider Theo M.
Published: April 2023

Supplementary Table S1. Characteristics of NSCLC cases, smoking-habit controls and non-smoking controls.
Supplementary Table 1 from Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy
Authors: Page David B. , Yuan Jianda , Redmond David , Wen Y Hanna , Durack Jeremy C. , Emerson Ryan , Solomon Stephen , Dong Zhiwan , Wong Phillip , Comstock Christopher , Diab Adi , Sung Janice , Maybody Majid , Morris Elizabeth , Brogi Edi , Morrow Monica , Sacchini Virgilio , Elemento Olivier , Robins Harlan , Patil Sujata , Allison James P. , Wolchok Jedd D. , Hudis Clifford , Norton Larry , McArthur Heather L.
Published: April 2023

Supplementary Table 1: TCRB sequencing sample IDs
Supplementary Figures S1 - S2 from Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells
Authors: Zahm Christopher D. , Colluru Viswa T. , McNeel Douglas G.
Published: April 2023

Flow cytometry gating strategies for data presented in Figures 1-6. Supplementary Figure S1. Representative dot plots and gating strategy for Figure 1. Supplementary Figure S2. Representative dot plots and gating strategy for Figure 2.
Supplemental Table 1. Statistical comparisons between negative peptide control and ATP6S1 peptides. from Immunity to the Vacuolar ATPase Complex Accessory Unit ATP6S1 in Patients with Malignant Melanoma
Authors: Zhou Jun , Gupta Meghna , Wu Xinqi , Yoon Charles , Giobbie-Hurder Anita , Hodi F. Stephen
Published: April 2023

P < 0.05 is considered to be significant.
Supplementary Figures 1 - 3 from Whole-Body Irradiation Increases the Magnitude and Persistence of Adoptively Transferred T Cells Associated with Tumor Regression in a Mouse Model of Prostate Cancer
Authors: Ward-Kavanagh Lindsay K. , Zhu Junjia , Cooper Timothy K. , Schell Todd D.
Published: April 2023

PDF file - 259K, Supplementary Figure 1. CD8+ T cell accumulation in the TRAMP prostate is tumor antigen-dependent. Supplementary Figure 2. Widespread disease regression in 2X WBI + TCR-IV treated mice. Supplementary Figure 3. Recovery from radiation-induced lymphopenia in TRAMP mice.
Supplementary Figure 3 from PD-1 Blockade Expands Intratumoral Memory T Cells
Authors: Ribas Antoni , Shin Daniel Sanghoon , Zaretsky Jesse , Frederiksen Juliet , Cornish Andrew , Avramis Earl , Seja Elizabeth , Kivork Christine , Siebert Janet , Kaplan-Lefko Paula , Wang Xiaoyan , Chmielowski Bartosz , Glaspy John A. , Tumeh Paul C. , Chodon Thinle , Pe'er Dana , Comin-Anduix Begoña
Published: April 2023

Gating strategy to study T cells subpopulations within tumor-infiltrating lymphocytes and PBMC. We represent dot-plots on the top of the figure, and a dendrogram displaying the gating strategy of eight phenotype markers, before applying Boolean gates, and posteriorly analyzed with the exhaustive expansion software. During gating by morphology, and excluding duplex, double positive live and CD3+ T cells were gated on CD8, CD4, CD45RA, CD45RO, CCR7, CD62L, CD27, CD57, CD95 and PD-1.
Supplemental Figure 2 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Authors: Gibson Heather M. , Veenstra Jesse J. , Jones Richard , Vaishampayan Ulka , Sauerbrey Michele , Bepler Gerold , Lum Lawrence , Reyes Joyce , Weise Amy , Wei Wei-Zen
Published: April 2023

RTK analysis of FMC primary tissue and cell lines.
Supplementary Figures S1 through S6 from Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells
Authors: Ohue Yoshihiro , Kurose Koji , Nozawa Ryohei , Isobe Midori , Nishio Yumi , Tanaka Tomonori , Doki Yoshinori , Hori Takashi , Fukuoka Junya , Oka Mikio , Nakayama Eiichi
Published: April 2023

Figure S1 - OS of lung adenocarcinoma patients with TILs. Figure S2 - Discriminant scores of each lung adenocarcinoma patient calculated by the discriminant function. Figure S3 - OS of lung adenocarcinoma patients belonging to predicted clusters with the study cohort and validation cohort. Figure S4 - Correlation of PD-L1 and Galectin-9 expression and T-cell infiltration in the tumor - Figure S5 - RT-PCR analysis of XAGE1 mRNA. Figure S6 - Effect of IFNgamma on PD-L1 and Galectin-9 expression in cell lines.
Supplementary Figure S3 from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20
Authors: Weiskopf Kipp , Anderson Katie L. , Ito Daisuke , Schnorr Peter J. , Tomiyasu Hirotaka , Ring Aaron M. , Bloink Kristin , Efe Jem , Rue Sarah , Lowery David , Barkal Amira , Prohaska Susan , McKenna Kelly M. , Cornax Ingrid , O'Brien Timothy D. , O'Sullivan M. Gerard , Weissman Irving L. , Modiano Jaime F.
Published: April 2023

Microscopic visualization demonstrates macrophage engulfment of CLBL-1 cells.
Supplementary Figure 6 from Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Authors: da Silva Ines Pires , Gallois Anne , Jimenez-Baranda Sonia , Khan Shaukat , Anderson Ana C. , Kuchroo Vijay K. , Osman Iman , Bhardwaj Nina
Published: April 2023

PDF file - 119K, Fig. S6. Tim-3 engagement by Galectin-9 on NK cells from healthy donors and melanoma patients inhibits their cytotoxicity.
Supplementary Figure 4 from Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Authors: da Silva Ines Pires , Gallois Anne , Jimenez-Baranda Sonia , Khan Shaukat , Anderson Ana C. , Kuchroo Vijay K. , Osman Iman , Bhardwaj Nina
Published: April 2023

PDF file - 87K, Fig. S4. Tim-3 is up-regulated in MD NK cells.
Supplemental figure 2: from Cross-talk between 4-1BB and TLR1–TLR2 Signaling in CD8+ T Cells Regulates TLR2′s Costimulatory Effects
Authors: Joseph Ann Mary , Srivastava Ratika , Zabaleta Jovanny , Davila Eduardo
Published: April 2023

Proliferation of 4-1BB-/- CD8+ T cells is not globally affected by the loss of 4-1BB.
Supplementary Figure 6 from Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice
Authors: Mota José M. , Leite Caio A. , Souza Lucas E. , Melo Paulo H. , Nascimento Daniele C. , de-Deus-Wagatsuma Virginia M. , Temporal Jessica , Figueiredo Florêncio , Noushmehr Houtan , Alves-Filho José C. , Cunha Fernando Q. , Rego Eduardo M.
Published: April 2023

AMD3100 inhibited the ability of post-sepsis bone marrow derived macrophages to increase tumor growth
Supplemental Figure 1: from Cross-talk between 4-1BB and TLR1–TLR2 Signaling in CD8+ T Cells Regulates TLR2′s Costimulatory Effects
Authors: Joseph Ann Mary , Srivastava Ratika , Zabaleta Jovanny , Davila Eduardo
Published: April 2023

Phenotypic analysis of WT, 4-1BB-/- and MyD88-/- CD8+ T cells treated with TLR1-TLR2 ligand.
Supplementary Figure 4 from Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice
Authors: Mota José M. , Leite Caio A. , Souza Lucas E. , Melo Paulo H. , Nascimento Daniele C. , de-Deus-Wagatsuma Virginia M. , Temporal Jessica , Figueiredo Florêncio , Noushmehr Houtan , Alves-Filho José C. , Cunha Fernando Q. , Rego Eduardo M.
Published: April 2023

Differences in intratumoral amounts of CD3+CD4+ and CD3+CD8+ cells were not detected.
Supplementary Figure 3 from Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice
Authors: Mota José M. , Leite Caio A. , Souza Lucas E. , Melo Paulo H. , Nascimento Daniele C. , de-Deus-Wagatsuma Virginia M. , Temporal Jessica , Figueiredo Florêncio , Noushmehr Houtan , Alves-Filho José C. , Cunha Fernando Q. , Rego Eduardo M.
Published: April 2023

Post-sepsis induces the accumulation of Tregs in the spleen and lymph nodes but not within the tumor.
Supplementary Figure 1 from Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice
Authors: Mota José M. , Leite Caio A. , Souza Lucas E. , Melo Paulo H. , Nascimento Daniele C. , de-Deus-Wagatsuma Virginia M. , Temporal Jessica , Figueiredo Florêncio , Noushmehr Houtan , Alves-Filho José C. , Cunha Fernando Q. , Rego Eduardo M.
Published: April 2023

Increased tumor progression was detected 30 and 60 days after CLP.
Table S5 from Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator
Authors: Kurebayashi Yutaka , Emoto Katsura , Hayashi Yuichiro , Kamiyama Ikuo , Ohtsuka Takashi , Asamura Hisao , Sakamoto Michiie
Published: April 2023

Univariate analysis of infiltrating immune cells stratified by histological subtypes
Table S4 from Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator
Authors: Kurebayashi Yutaka , Emoto Katsura , Hayashi Yuichiro , Kamiyama Ikuo , Ohtsuka Takashi , Asamura Hisao , Sakamoto Michiie
Published: April 2023

Multivariate analysis of clinicopatholocal factors and immunosubtypes
Table S3 from Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator
Authors: Kurebayashi Yutaka , Emoto Katsura , Hayashi Yuichiro , Kamiyama Ikuo , Ohtsuka Takashi , Asamura Hisao , Sakamoto Michiie
Published: April 2023

Combinations of infiltrating immune cells with high correlations (r > 0.7)
Supplementary Figure 1 from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Authors: Boyerinas Benjamin , Jochems Caroline , Fantini Massimo , Heery Christopher R. , Gulley James L. , Tsang Kwong Yok , Schlom Jeffrey
Published: April 2023

Dose response curves for avelumab-mediated ADCC assays of 3 human cancer cell lines using purified NK cells from the same healthy donor as effectors at an effector:target ratio of 25:1.
Supplemental Figures 1 through 5 from Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator
Authors: Kurebayashi Yutaka , Emoto Katsura , Hayashi Yuichiro , Kamiyama Ikuo , Ohtsuka Takashi , Asamura Hisao , Sakamoto Michiie
Published: April 2023

Figure S1. Infiltration of immune cells and grades of histological subtypes. Figure S2. Infiltration of interfollicular plasma cells and Kaplan-Meier curves for DFS. Figure S3. Infiltration of interfollicular mast cells and Kaplan-Meier curves for DFS. Figure S4. Plasma cell/CD8 ratio and Kaplan-Meier curves for DFS. Figure S5. Immunohistochemical staining for immunoglobulins and PD-L1.
Supplementary Figure 1 from Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Authors: Tumeh Paul C. , Hellmann Matthew D. , Hamid Omid , Tsai Katy K. , Loo Kimberly L. , Gubens Matthew A. , Rosenblum Michael , Harview Christina L. , Taube Janis M. , Handley Nathan , Khurana Neharika , Nosrati Adi , Krummel Matthew F. , Tucker Andrew , Sosa Eduardo V. , Sanchez Phillip J. , Banayan Nooriel , Osorio Juan C. , Nguyen-Kim Dan L. , Chang Jeremy , Shintaku I. Peter , Boasberg Peter D. , Taylor Emma J. , Munster Pamela N. , Algazi Alain P. , Chmielowski Bartosz , Dummer Reinhard , Grogan Tristan R. , Elashoff David , Hwang Jimmy , Goldinger Simone M. , Garon Edward B. , Pierce Robert H. , Daud Adil
Published: April 2023

Univariate Analysis of Pretreatment prognostic factors in the Discovery cohort.
Supplementary Figure 3 from ERK-Dependent Downregulation of the Atypical Chemokine Receptor D6 Drives Tumor Aggressiveness in Kaposi Sarcoma
Authors: Savino Benedetta , Caronni Nicoletta , Anselmo Achille , Pasqualini Fabio , Borroni Elena Monica , Basso Gianluca , Celesti Giuseppe , Laghi Luigi , Tourlaki Athanasia , Boneschi Vinicio , Brambilla Lucia , Nebuloni Manuela , Vago Gianluca , Mantovani Alberto , Locati Massimo , Bonecchi Raffaella
Published: April 2023

PDF file - 123K, Supplemental Figure 3 - Increased ERK activation and macrophage infiltration in rapid progressing KS lesions.
Supplementary Figure 2 from ERK-Dependent Downregulation of the Atypical Chemokine Receptor D6 Drives Tumor Aggressiveness in Kaposi Sarcoma
Authors: Savino Benedetta , Caronni Nicoletta , Anselmo Achille , Pasqualini Fabio , Borroni Elena Monica , Basso Gianluca , Celesti Giuseppe , Laghi Luigi , Tourlaki Athanasia , Boneschi Vinicio , Brambilla Lucia , Nebuloni Manuela , Vago Gianluca , Mantovani Alberto , Locati Massimo , Bonecchi Raffaella
Published: April 2023

PDF file - 90K, Supplemental Figure 2 - D6- and D6+KS tumors have equal necrotic areas.
Supplementary Figure 1 from ERK-Dependent Downregulation of the Atypical Chemokine Receptor D6 Drives Tumor Aggressiveness in Kaposi Sarcoma
Authors: Savino Benedetta , Caronni Nicoletta , Anselmo Achille , Pasqualini Fabio , Borroni Elena Monica , Basso Gianluca , Celesti Giuseppe , Laghi Luigi , Tourlaki Athanasia , Boneschi Vinicio , Brambilla Lucia , Nebuloni Manuela , Vago Gianluca , Mantovani Alberto , Locati Massimo , Bonecchi Raffaella
Published: April 2023

PDF file - 123K, Supplemental Figure 1 - D6+KS but not D6- KS cells display chemokine scavenging activity.
Supplementary Figure 1 from Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Authors: Gabrielson Andrew , Wu Yunan , Wang Hongkun , Jiang Jiji , Kallakury Bhaskar , Gatalica Zoran , Reddy Sandeep , Kleiner David , Fishbein Thomas , Johnson Lynt , Island Eddie , Satoskar Rohit , Banovac Filip , Jha Reena , Kachhela Jaydeep , Feng Perry , Zhang Tiger , Tesfaye Anteneh , Prins Petra , Loffredo Christopher , Marshall John , Weiner Louis , Atkins Michael , He Aiwu Ruth
Published: April 2023

Flowchart of image analysis process.
Supplemental Table 2 from Clinical Response of a Patient to Anti–PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors
Authors: Shah Shalin , Ward James E. , Bao Riyue , Hall Curtis R. , Brockstein Bruce E. , Luke Jason J.
Published: April 2023

List of 1,015 genes used for identification of T cell-inflamed, intermediate, and non-T cell-inflamed tumor subtypes.
Supplemental Table 1 from Clinical Response of a Patient to Anti–PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors
Authors: Shah Shalin , Ward James E. , Bao Riyue , Hall Curtis R. , Brockstein Bruce E. , Luke Jason J.
Published: April 2023

List of TCGA samples included in this study.
Supplementary Movie 3 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Authors: Davenport Alexander J. , Jenkins Misty R. , Cross Ryan S. , Yong Carmen S. , Prince H. Miles , Ritchie David S. , Trapani Joseph A. , Kershaw Michael H. , Darcy Phillip K. , Neeson Paul J.
Published: April 2023

Movie 3. CAR.OT-I cells co-cultured with MC57-HER2 cells.
Supplementary Methods from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Authors: Davenport Alexander J. , Jenkins Misty R. , Cross Ryan S. , Yong Carmen S. , Prince H. Miles , Ritchie David S. , Trapani Joseph A. , Kershaw Michael H. , Darcy Phillip K. , Neeson Paul J.
Published: April 2023

Supplementary Methods. Time lapse live video (TLLV) microscopy
Supplementary Figure 3 from Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes
Authors: Kitano Shigehisa , Postow Michael A. , Ziegler Carly G.K. , Kuk Deborah , Panageas Katherine S. , Cortez Czrina , Rasalan Teresa , Adamow Mathew , Yuan Jianda , Wong Philip , Altan-Bonnet Gregoire , Wolchok Jedd D. , Lesokhin Alexander M.
Published: April 2023

PDF file - 88K, Supplemental Figure 3. PBMCs from metastatic melanoma patients treated with ipilimumab depleted of CD14-expressing cells were stimulated to proliferate with OKT-3 and IL-2. CFSE dilution of CD3+ T cells in the culture is measured in the absence of CD14+ cells or with CD14+ cells added back.
Supplementary Figures 1 and 2 and Supplementary Tables 1 through 5 from MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer
Authors: Dou Ruoxu , Nishihara Reiko , Cao Yin , Hamada Tsuyoshi , Mima Kosuke , Masuda Atsuhiro , Masugi Yohei , Shi Yan , Gu Mancang , Li Wanwan , da Silva Annacarolina , Nosho Katsuhiko , Zhang Xuehong , Meyerhardt Jeffrey A. , Giovannucci Edward L. , Chan Andrew T. , Fuchs Charles S. , Qian Zhi Rong , Ogino Shuji
Published: April 2023

Figure S1. Quantitative reverse-transcription PCR assays for let-7a, let-7b, and RNU6-2 using 10-fold dilution series from the same specimen. Figure S2. let-7a and let-7b expression in colorectal cancer. Table S1. Inter-assay coefficients of variation in quantitative reverse-transcription PCR assays for let-7a, let-7b and RNU6-2. Table S2. Clinical, pathological, and molecular characteristics according to tumor let-7b expression in 792 colorectal cancer cases. Table S3. Association of tumor let-7a and let-7b expression with disease stage. Table S4. Spearman's rank-correlation coefficients between the densities of T-cells. Table S5. Tumor let-7a expression and patient mortality in the 518 cases with CD45RO+ T-cell density data.
Supplementary Figures 1 through 11 from MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation
Authors: Yaddanapudi Kavitha , Rendon Beatriz E. , Lamont Gwyneth , Kim Eun Jung , Al Rayyan Numan , Richie Jamaal , Albeituni Sabrin , Waigel Sabine , Wise Ashley , Mitchell Robert A.
Published: April 2023

Supplemental Figure 1. MIF-inhibitor treatment does not alter the viability of melanoma MDSCs or A375 melanoma cell line and melanoma patient-derived MDSCs show increased levels of reactive oxygen species (ROS). Supplemental Figure 2. Characterization of myeloid cell populations in cultured normal monocytes and in A375:monocyte co-cultures. Supplemental Figure 3. MIF inhibition during melanoma cell line-induced MDSC alters the acquisition of MDSC phenotype. Supplemental Figure 4. Conditioned media from A375 cells fail to induce myeloid derived suppressive function in CD14+ monocytes and MIF inhibition in melanoma cell line-educated CD11b+HLA-DR- MDSCs reduces their suppressive function. Supplemental Figure 5. MIF inhibition in melanoma cell line-educated MDSCs reduces their suppressive function. Supplemental Figure 6. MIF deficiency in murine bone marrow-derived MDSCs (BM-MDSC) reduces their in vitro suppressive activity. Supplemental Figure 7. MIF deficiency in murine CD11b+GR1+ bone marrow-derived MDSCs (BM-MDSC) reduces their in vitro suppressive activity. Supplemental Figure 8. Melanoma cell line-induced MDSC transciptome reveals a unique gene expression profile that is largely reversed to normal monocyte levels by MIF inhibition. Supplemental Figure 9. Schematic representation of the timeline for in vitro A375-MDSC induction, A375-MDSC differentiation and different 4-IPP treatment regimens. Supplemental Figure 10. MIF-deficient murine bone marrow-derived MDSCs (BM-MDSC) differentiate into cells with an immunostimulatory DC phenotype and function. Supplemental Figure 11. MIF inhibition in melanoma cell line-educated MDSCs induces an immunostimulatory dendritic cell (DC) function via suppression of PGE2 production.
Supplementary Figure 4 from T-cell Expression of IL10 Is Essential for Tumor Immune Surveillance in the Small Intestine
Authors: Dennis Kristen L. , Saadalla Abdulrahman , Blatner Nichole R. , Wang Shuya , Venkateswaran Vysak , Gounari Fotini , Cheroutre Hilde , Weaver Casey T. , Roers Axel , Egilmez Nejat K. , Khazaie Khashayarsha
Published: April 2023

Intra-polyp perforin (green) and granzyme B (red) immunofluorescent co-staining (yellow) on 4 um sections from APCdelta468 and IL2pIL-10 APCdelta468 mice; x400.
Supplementary Figure 2 from T-cell Expression of IL10 Is Essential for Tumor Immune Surveillance in the Small Intestine
Authors: Dennis Kristen L. , Saadalla Abdulrahman , Blatner Nichole R. , Wang Shuya , Venkateswaran Vysak , Gounari Fotini , Cheroutre Hilde , Weaver Casey T. , Roers Axel , Egilmez Nejat K. , Khazaie Khashayarsha
Published: April 2023

(A-D) Representative immunofluorescent staining images of B6 small intestinal and APCdelta468 polyp and marginal tissue. (A) 200X images showing CD4 (red), Foxp3 (green), and DAPI (blue). (B) 400X images showing Foxp3 (green), IL-10 (red), and DAPI (blue). (C) 400X images showing CD4 (green), IL-10 (red), double positive CD4+IL-10+ (yellow), and DAPI (blue).
Supplementary Figure Legends from B7-H4 Expression by Nonhematopoietic Cells in the Tumor Microenvironment Promotes Antitumor Immunity
Authors: Rahbar Ramtin , Lin Albert , Ghazarian Magar , Yau Helen-Loo , Paramathas Sangeetha , Lang Philipp A. , Schildknecht Anita , Elford Alisha R. , Garcia-Batres Carlos , Martin Bernard , Berman Hal K. , Leong Wey L. , McCready David R. , Reedijk Michael , Done Susan J. , Miller Naomi , Youngson Bruce , Suh Woong-Kyung , Mak Tak W. , Ohashi Pamela S.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure S2 from IL17A-Mediated Endothelial Breach Promotes Metastasis Formation
Authors: Kulig Paulina , Burkhard Sara , Mikita-Geoffroy Joanna , Croxford Andrew L. , Hövelmeyer Nadine , Gyülvészi Gabor , Gorzelanny Christian , Waisman Ari , Borsig Lubor , Becher Burkhard
Published: April 2023

Supplementary Figure S2
Supplementary Table S1 from Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
Authors: Johnson Douglas B. , Lovly Christine M. , Flavin Marisa , Panageas Katherine S. , Ayers Gregory D. , Zhao Zhiguo , Iams Wade T. , Colgan Marta , DeNoble Sarah , Terry Charles R. , Berry Elizabeth G. , Iafrate A. John , Sullivan Ryan J. , Carvajal Richard D. , Sosman Jeffrey A.
Published: April 2023

Mutations assessed at VICC.
Supplemental Figure Legends from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
Authors: Wang Enxiu , Wang Liang-Chuan , Tsai Ching-Yi , Bhoj Vijay , Gershenson Zack , Moon Edmund , Newick Kheng , Sun Jing , Lo Albert , Baradet Timothy , Feldman Michael D. , Barrett David , Puré Ellen , Albelda Steven , Milone Michael C.
Published: April 2023

Figure legends for supplemental data.
Supplemental Tables 1 - 2, Figures 1 - 9 from Robust Antitumor Effects of Combined Anti–CD4-Depleting Antibody and Anti–PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice
Authors: Ueha Satoshi , Yokochi Shoji , Ishiwata Yoshiro , Ogiwara Haru , Chand Krishant , Nakajima Takuya , Hachiga Kosuke , Shichino Shigeyuki , Terashima Yuya , Toda Etsuko , Shand Francis H.W. , Kakimi Kazuhiro , Ito Satoru , Matsushima Kouji
Published: April 2023

Table S1. Antibodies for flow cytometry and immunohistostaining. Table S2. Primers and probes used in real-time PCR. Supplementary Figure S1. Generation of B16F10-ÃŽ?hLNGFR transfected cells. Supplementary Figure S2. Optimization of the timing and dose for the administration of anti-CD4 mAb monotherapy. Supplementary Figure S3. Anti-CD4 mAb treatment decreases numbers of CD4+ T cells and pDCs in the blood, lymph nodes, spleen and tumor. Supplementary Figure S4. Intravascular staining distinguishes the intravascular and parenchymal leukocyte fractions in tumor tissue. Supplementary Figure S5. Anti-CD4 mAb treatment enhances the killing activity of tumor-infiltrating CD8+ T cells. Supplementary Figure S6. Anti-CD4 mAb treatment systemically increases the number of CD8+ CD44hi PD-1+ T cells. Supplementary Figure S7. Anti-CD4 mAb treatment causes proliferation of tumor-specific CD8+ T cells. Supplementary Figure S8. Anti-CD4 mAb treatment enhances proliferation of tumor-specific CD8+ T cells in the dLN. Supplementary Figure S9. Anti-CD4 mAb treatment or combination treatment with anti-CD4 and anti-PD-1 or PD-L1 mAbs induces anti-tumor gene expression within the tumor.
Supplementary Tables 1 - 4 from Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab
Authors: Kwek Serena S. , Lewis Jera , Zhang Li , Weinberg Vivian , Greaney Samantha K. , Harzstark Andrea L. , Lin Amy M. , Ryan Charles J. , Small Eric J. , Fong Lawrence
Published: April 2023

Supplementary Table S1. Patient characteristics by cohort. Supplementary Table S2. Treatment-related toxicity. Supplementary Table S3. Individual clinical response of patients treated with ipilimumab at {greater than or equal to} 3mg/kg/dose. Supplementary Table S4. Comparison of absolute counts of T cell subsets between LTS and STS.
Supplemental Methods, Tables 1 - 3, Figures 1 - 16 from Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
Authors: Frigault Matthew J. , Lee Jihyun , Basil Maria Ciocca , Carpenito Carmine , Motohashi Shinichiro , Scholler John , Kawalekar Omkar U. , Guedan Sonia , McGettigan Shannon E. , Posey Avery D. , Ang Sonny , Cooper Laurence J.N. , Platt Jesse M. , Johnson F. Brad , Paulos Chrystal M. , Zhao Yangbing , Kalos Michael , Milone Michael C. , June Carl H.
Published: April 2023

Table S1: Expression of c-Met and Mesothelin mRNA in activated CD4 T Cells. Table S2: Genes upregulated in CD4+ T cells of healthy human adults expressing c-Met IgG4 continuous CAR or CD19 CD8α non-continuous CAR on day 11. Table S3: Genes downregulated in CD4+ T cells of healthy human adults expressing c-Met IgG4 continuous CAR or CD19 CD8α non-continuous CAR on day 11. Figure S1. Chimeric antigen receptor constructs and relative expression levels. Figure S2. CAR T cells with constitutive proliferation retain specific cytotoxicity. Figure S3. c-Met and mesothelin expression are not detected on human CD4+ T cells. Figure S4. Supernatant from CARs displaying the growth phenotype induces activation of naïve unstimulated T cells. Figure S5.The role of fetal bovine serum in the constitutive growth of c-Met IgG4 28ζ CAR T cells. Figure S6. A) CARs with a constitutive growth phenotype display a unique gene signature. B) CAR T cells with a constitutive growth phenotype display distinct transcription factors. Figure S7. Genome-wide microarray analysis of CAR T cells with constitutive proliferation. Figure S8. Distinct gene expression signature of CAR T cells with constitutive proliferation. Figure S9. CAR T cells with constitutive proliferation have ligand-independent NFAT activation. Figure S10. Transgene expression levels are sufficient to convey the constitutive CAR growth phenotype. Figure S11. Constitutive CAR T cell proliferation results in differentiation and evolution of a distinct cell surface phenotype. Figure S12. Effects of stimulation and cell culture on differentiation of non-transduced T cells. Figure S13. Temporal patterns of telomere restriction fragment length (TRF) in continuous CAR T cells and mock transduced T cells. Figure S14. CAR T cells with a constitutive growth phenotype retain a diverse TCR Vβ repertoire. Figure S15. Engraftment and proliferation of continuous CAR T cells in NSG mice. Figure S16. PGK100 promoter results in antigen driven accumulation of CAR T cells in tissue but not blood.
Supplementary Figures 1 through 9 and Supplementary Materials and Methods from Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases
Authors: Hu Jiemiao , Bernatchez Chantale , Zhang Liangfang , Xia Xueqing , Kleinerman Eugenie S. , Hung Mien-Chie , Hwu Patrick , Li Shulin
Published: April 2023

Fig. S1. Gradual reduction of Rae-1 during tumor progression. Fig. S2. Induction of Rae-1 by chemotherapy in vitro but not in vivo. Fig. S3 Effector molecule perforin expression in tumors after indicated treatments. Fig. S4 Rae-1 expression is not induced by IL-12 plus doxorubicin in normal tissues. Fig. S5 Accumulation of NKG2D+CD8+ T cells in tumors after IL-12 plus doxorubicin treatment. Fig. S6 Immunochemistry staining of Rae-1 and TUNEL assay in tumor sections. Fig. S7 Rae-1 induction by IL-12 plus doxorubicin only occurs on tumor cells in vivo. Fig. S8 Antitumor cytotoxicity of IL-12 plus doxorubicin abolished by depletion of CD8+ T cells, but not CD4+ T cells or NK cells. Fig. S9 Enrichment of NK cells, CD4+ T cells, or CD8+ T cells in splenocytes collected from BALB/c mice treated with IL-12 plus doxorubicin.
Supplementary Table 2 from Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Authors: Roemer Margaretha G.M. , Advani Ranjana H. , Redd Robert A. , Pinkus Geraldine S. , Natkunam Yasodha , Ligon Azra H. , Connelly Courtney F. , Pak Christine J. , Carey Christopher D. , Daadi Sarah E. , Chapuy Bjoern , de Jong Daphne , Hoppe Richard T. , Neuberg Donna S. , Shipp Margaret A. , Rodig Scott J.
Published: April 2023

Outcome (progression-free survival) - Cox multivariable models for beta2M
Supplementary Figure Legends from Prognostic Significance of CD169+ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma
Authors: Saito Yoichi , Ohnishi Koji , Miyashita Azusa , Nakahara Satoshi , Fujiwara Yukio , Horlad Hasita , Motoshima Takanobu , Fukushima Satoshi , Jinnin Masatoshi , Ihn Hironobu , Takeya Motohiro , Komohara Yoshihiro
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 1.Optimization IHC on pilot series of cHL cases. from Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Authors: Roemer Margaretha G.M. , Advani Ranjana H. , Redd Robert A. , Pinkus Geraldine S. , Natkunam Yasodha , Ligon Azra H. , Connelly Courtney F. , Pak Christine J. , Carey Christopher D. , Daadi Sarah E. , Chapuy Bjoern , de Jong Daphne , Hoppe Richard T. , Neuberg Donna S. , Shipp Margaret A. , Rodig Scott J.
Published: April 2023

Three distinct patterns of staining of HRS cell membranes were observed relative to the staining of reactive inflammatory cells: "positive" (Pos), "decreased" (Dec) and "negative" (Neg) for β2M, MHC class I and MHC class II. CHL #1: β2M and MHC class I positive, MHC class II negative; cHL #2: beta2M and MHC class I decreased, MHC class II positive; cHL #3: beta2M and MHC class I negative, MHC class II decreased. Black arrows highlight individual HRS cells or two adjacent HRS cells with distinct patterns of membrane staining, as indicated.
Supplementary Table 1 from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
Authors: Dammeijer Floris , Lievense Lysanne A. , Kaijen-Lambers Margaretha E. , van Nimwegen Menno , Bezemer Koen , Hegmans Joost P. , van Hall Thorbald , Hendriks Rudi W. , Aerts Joachim G.
Published: April 2023

Antibodies used in the experiments
Supplementary Figures S1 through S7 from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
Authors: Dammeijer Floris , Lievense Lysanne A. , Kaijen-Lambers Margaretha E. , van Nimwegen Menno , Bezemer Koen , Hegmans Joost P. , van Hall Thorbald , Hendriks Rudi W. , Aerts Joachim G.
Published: April 2023

Figure S1; the AC29 mesothelioma tumor model has a more dominant TAM phenotype compared to the AB1 tumor model. Figure S2; GM-CSF cultured dendritic cells are minimally affected by PLX3397. Figure S3; Gating of immune cell subsets in the blood of mice during therapy. Figure S4; CD4/CD8 Double positive T cells are most abundant after DC- TAM-depletion combination therapy and highest in proliferation marker Ki-67 compared to single positive CD8+ T cells. Figure S5; Similar patterns in myeloid and lymphoid cell dynamics in response to treatment were made in the BALB/c (AB1) tumor model compared to the CBA/j (AC29) model. The TME immune contexture at day 15 post tumor injection is differentially modulated by PLX3397 and DC-therapy. Figure S7; TAM-depletion improves CD8+ T-cell exhaustion status characterized by decreased PD1, LAG3, TIM3 and CD8 expression
Figures S4 to S9 from VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
Authors: Wu Xinqi , Giobbie-Hurder Anita , Liao Xiaoyun , Lawrence Donald , McDermott David , Zhou Jun , Rodig Scott , Hodi F. Stephen
Published: April 2023

Supplementary Figure S4. IL-1a, TNFa and IL-1b induce adhesion molecule expression and promote T cell adhesion onto human dermal microvascular endothelial cells (HDMEC). Supplementary Figure S5. VEGF inhibits TNFa-mediated ICAM-1expression in TEC and HUVEC. Supplementary Figure S6. IP-10 induces migration of activated T cells across HDMEC. Supplementary Figure S7. Kaplan-Meier survival curves based on fold-changes of circulating IL-1a, TNFa, IFNa2, IL-8, IP-10, and GRO in response to Ipi-Bev treatment. Supplementary Figure S8. Cytokines/chemokines and clinical outcomes in Ipi-Bev treated patients. Supplementary Figure S9. Ipi-Bev therapy influenced circulating endothelial cells (CEC) in melanoma patients.
Supplementary Tables and Legends from T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy
Authors: Andersen Rikke , Westergaard Marie Christine Wulff , Kjeldsen Julie Westerlin , Müller Anja , Pedersen Natasja Wulff , Hadrup Sine Reker , Met Özcan , Seliger Barbara , Kromann-Andersen Bjarne , Hasselager Thomas , Donia Marco , Svane Inge Marie
Published: April 2023

Supplementary tables 1-4 and legends
Table S1 from Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Authors: Kouo Theodore , Huang Lanqing , Pucsek Alexandra B. , Cao Minwei , Solt Sara , Armstrong Todd , Jaffee Elizabeth
Published: April 2023

Antibody-reactive proteins identified by a functional seroproteomics approach
Figure S2 from Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Authors: Kouo Theodore , Huang Lanqing , Pucsek Alexandra B. , Cao Minwei , Solt Sara , Armstrong Todd , Jaffee Elizabeth
Published: April 2023

Tumor infiltrating lymphocytes (TIL) were isolated 5 days post adoptive transfer according to the materials and methods section. Cells were gated for Thy1.2 expression. A) Galectin-3 wildtype (WT) high avidity CD8+ T cells were adoptively transferred into either galectin-3 WT (red) or galectin-3 KO neu-N (blue) recipient mice. Histogram overlays show differences in galectin-3 MFI between the two groups with respect to isotype control staining (orange). B) Galectin-3 staining is now shown on galectin-3 KO high avidity CD8+ T cells adoptively transferred into a galectin-3 KO neu-N recipient (blue) with respect to an isotype control (red). C) TCR avidity is compared between galectin-3 WT high avidity CD8+ T cells from a galectin-3 WT neu-N recipient and galectin-3 KO high avidity CD8+ T cells from a galectin-3 KO neu-N recipient. TCR avidity was assessed by staining with a 1:100 dilution of MHC I Dq tetramer loaded with the RNEU420-429 (P50) peptide. This experiment was repeated twice with similar results. D) Histogram overlays demonstrating differences in surface galectin-3 MFI on adoptively transferred high avidity tumor specific CD8+ T cells (Thy1.2+) vs. endogenous CD8+ T cells in the tumor microenvironment (Thy1.2-)
Supplementary Figure Legends from Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
Authors: Fromm George , de Silva Suresh , Giffin Louise , Xu Xin , Rose Jason , Schreiber Taylor H.
Published: April 2023

Figure legends for Supplemental Figures 1-5
Supplementary Table 1 from Untreated Stage IV Melanoma Patients Exhibit Abnormal Monocyte Phenotypes and Decreased Functional Capacity
Authors: Chavan Rahul , Salvador Daniela , Gustafson Michael P. , Dietz Allan B. , Nevala Wendy , Markovic Svetomir N.
Published: April 2023

PDF file - 62K, Immunophenotype Panel.
Supplementary Figure S4 from Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib
Authors: Frazao Alexandra , Colombo Marina , Fourmentraux-Neves Emmanuelle , Messaoudene Meriem , Rusakiewicz Sylvie , Zitvogel Laurence , Vivier Eric , Vély Frédéric , Faure Florence , Dréno Brigitte , Benlalam Houssem , Bouquet Fanny , Savina Ariel , Pasmant Eric , Toubert Antoine , Avril Marie-Françoise , Caignard Anne
Published: April 2023

Vemurafenib and Batimastat modulate the expression of NK cell ligands by melanoma cells.
Supplementary Figure S3 from Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib
Authors: Frazao Alexandra , Colombo Marina , Fourmentraux-Neves Emmanuelle , Messaoudene Meriem , Rusakiewicz Sylvie , Zitvogel Laurence , Vivier Eric , Vély Frédéric , Faure Florence , Dréno Brigitte , Benlalam Houssem , Bouquet Fanny , Savina Ariel , Pasmant Eric , Toubert Antoine , Avril Marie-Françoise , Caignard Anne
Published: April 2023

Effect of Vemurafenib treatment on melanoma cell lysis.
Supplementary Figure 6 from The Promotion of Breast Cancer Metastasis Caused by Inhibition of CSF-1R/CSF-1 Signaling Is Blocked by Targeting the G-CSF Receptor
Authors: Swierczak Agnieszka , Cook Andrew D. , Lenzo Jason C. , Restall Christina M. , Doherty Judy P. , Anderson Robin L. , Hamilton John A.
Published: April 2023

PDF file - 76K, Supplementary Figure 6: Blockade of CSF-1R increases serum G-CSF levels in 4T1.2 and EMT6.5 tumor-bearing mice.
Supplementary Table 6 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers
Authors: Yao Jun , Caballero Otavia L. , Yung W.K. Alfred , Weinstein John N. , Riggins Gregory J. , Strausberg Robert L. , Zhao Qi
Published: April 2023

XLSX file - 29K, Supplemental Table S6. List of Coxph Regression P values of CT genes in eight cancer types.
Supplementary Table 5 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers
Authors: Yao Jun , Caballero Otavia L. , Yung W.K. Alfred , Weinstein John N. , Riggins Gregory J. , Strausberg Robert L. , Zhao Qi
Published: April 2023

XLSX file - 41K, Supplemental Table S5. Correlation coefficient of CT gene expression and DNA methylation in cancers
Supplementary Table 4 from Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity
Authors: Zhang Xiuli , Kim Samuel , Hundal Jasreet , Herndon John M. , Li Shunqiang , Petti Allegra A. , Soysal Savas D. , Li Lijin , McLellan Mike D. , Hoog Jeremy , Primeau Tina , Myers Nancy , Vickery Tammi L. , Sturmoski Mark , Hagemann Ian S. , Miller Chris A. , Ellis Matthew J. , Mardis Elaine R. , Hansen Ted , Fleming Timothy P. , Goedegebuure S. Peter , Gillanders William E.
Published: April 2023

Characterization of tier 1 mutations identified in WHIM37 through NSG.
Supplementary Table 3 from Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity
Authors: Zhang Xiuli , Kim Samuel , Hundal Jasreet , Herndon John M. , Li Shunqiang , Petti Allegra A. , Soysal Savas D. , Li Lijin , McLellan Mike D. , Hoog Jeremy , Primeau Tina , Myers Nancy , Vickery Tammi L. , Sturmoski Mark , Hagemann Ian S. , Miller Chris A. , Ellis Matthew J. , Mardis Elaine R. , Hansen Ted , Fleming Timothy P. , Goedegebuure S. Peter , Gillanders William E.
Published: April 2023

Characterization of tier 1 mutations identified in WHIM35 through NSG.